Menu
Not yet recruiting NCT06602284

A Full Face Study to Evaluate the Efficacy of Dermapen 4™ Microneedling Device in Addition with MG-CLR Serum for Acne Treatment Over 12 Weeks.

Phase II / Phase III Interventional Acne

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Dermapen 4™.
Who it may be relevant to
Registry conditions: Acne. Basic parameters: 18 years — 45 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Full Face, Baseline Controlled Study to Evaluate the Efficacy of Dermapen 4™ Microneedling Device in Conjunction with MG-CLR Serum for Acne Treatment Over 12 Weeks.

Overview

This study is conducted to check how well the Dermapen 4™ microneedling device works with MG-CLR serum for treating acne over 12 weeks.

Interventions

  • Combination product Dermapen 4™
    Dermapen 4™ conjunction with MG-CLR

Primary outcome measures

  • Acne severity [Time frame: 13 weeks]

Eligibility criteria

Inclusion criteria

  • Female subjects aged between 18-45 years (both ages inclusive)
  • Fitzpatrick skin phototype I to VI.
  • Subjects having IGA score of 2 and 3.
  • Subjects who have not received any kind of treatment for acne 1 month before the start of the study.
  • Subject free of excessive hair, cuts, abrasions, fissures, wounds, lacerations, or any other skin conditions on the face.
  • Subjects who agree not to use any other product/treatment/home remedy/ except the provided products on their face during the study period

Exclusion criteria

  • Subjects with known skin condition that may impact the assessment.
  • Subjects with active Herpes labialis infection.
  • Subjects known to have bleeding and clotting disorders (self-declared).
  • Subjects known to have connective tissue disorders.
  • Subjects with any other signs of significant local irritation or skin disease.
  • Subjects currently taking any medication, which the investigator believes may influence the interpretation of the data.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

United States · 1 center
  • Skin Wellness Dermatology — Birmingham

Identifiers

NCT: NCT06602284 · SKIN/EMAC/2024-01

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗